代谢功能障碍相关的脂肪性肝病治疗及热门靶点的药物研究进展

Research progress in the current treatment and drugs to popular targets for metabolic dysfunction-associated steatotic liver disease

代谢功能障碍相关的脂肪性肝病发病率高、发病机制复杂性,与肥胖、代谢紊乱和心血管等疾病息息相关。随着生活水平的提高,这类疾病的患病率在我国呈逐年上升趋势,甚至超过全球平均值。治疗此类疾病的药物研发一直是各大药企和科研机构关注的热点。本文概述了现有的此类疾病的治疗方法,以及最热门靶点药物的最新研究进展。

Metabolic dysfunction-associated steatotic liver disease(MASLD)related diseases have the characteristics of high incidence rate and complex pathogenesis,which are closely related to obesity,metabolic disorders and cardiovascular diseases.With the improvement of living standards,the incidence of MASLD in China has been increasing year by year,even exceeding the global average.The research and development of such drugs has always been a hot topic of concern for major pharmaceutical companies and research institutions.The article reviewed the available treatment methods,as well as the latest advances on drugs to the most popular target of MASLD.